1
Wayne R Gombotz, Michael S Healy, Larry R Brown: Very low temperature casting of controlled release microspheres. Enzytech, Kilpatrick & Cody, May 28, 1991: US05019400 (302 worldwide citation)

A process for preparing microspheres using very cold temperatures to freeze polymer-biologically active agent mixtures into polymeric microspheres with very high retention of biological activity and material. Polymer is dissolved in a solvent together with an active agent that can be either dissolve ...


2
Wayne R Gombotz, Michael S Healy, Larry R Brown, Henry E Auer: Process for producing small particles of biologically active molecules. Alkermes Controlled Therapeutics, Hamilton Brook Smith & Reynolds P C, May 27, 2003: US06569458 (64 worldwide citation)

Small diameter particles of biologically active molecules are produced by atomizing solutions of the molecules through a nozzle into very cold liquified gases, which immediately freeze the atomized droplets. The resulting frozen particles having diameters of approximately 10 to 90 micrometers are ly ...


3
Wayne R Gombotz, SiowFong Wee: Controlled release polypeptide compositions and methods of treating inflammatory bowel disease. Immunex Corporation, Julie K Smith, March 14, 2000: US06036978 (61 worldwide citation)

The invention pertains to a controlled release pharmaceutical formulation that has an effective amount of a polypeptide selected from the group consisting of: (a) TNFR, (b) IL-1R, (c) IL-1ra, (d) IL-6R and (e) a monoclonal antibody that is immunoreactive against TNF, IL-6 or IL-1; wherein the polype ...


4
Wayne R Gombotz, Dean K Pettit, Susan C Pankey: Prolonged release of GM-CSF. Immunex Corporation, Diana K Sheiness, August 14, 2001: US06274175 (41 worldwide citation)

Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings th ...


5
Wayne R Gombotz, Siow Fong Wee, William C Fanslow III: Vaccine delivery system. Immunex Corporation, Patricia Anne Perkins, Janis C Henry, May 4, 1999: US05900238 (21 worldwide citation)

Compositions comprising an immunogenic amount of an antigen encapsulated in a stabilized hydrogel microbead are disclosed. The compositions provide a delivery system for antigens such as vaccines. Also provided are methods of stimulating an immune response comprising administration of the inventive ...


6
Wayne R Gombotz, Russell J Mumper, Allan S Hoffman, Lisa S Bouchard: Methods and compositions for the oral delivery of therapeutic agents. University of Washington, Bristol Myers Squibb Company, Christensen O Connor Johnson & Kindness, September 19, 1995: US05451411 (20 worldwide citation)

Alginate beads are employed as a site specific oral delivery system for cationic therapeutic agents, such as TGF-.beta..sub.1, designed to target the agents to the luminal side of the small intestine. Improved delivery of bioactive material is obtained by: 1) incorporating selected polyanions in the ...


7
Wayne R Gombotz, Richard L Remmele Jr: Stable aqueous formulation of a soluble TNF receptor and arginine. Immunex Corporation, Kathleen Fowler, Randolph Mohr, January 19, 2010: US07648702 (16 worldwide citation)

The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.


8
Wayne R Gombotz, Richard L Remmele Jr: Polypeptide formulation. Immunex Corporation, Randolph N Mohr, Kathleen Fowler, February 21, 2012: US08119604 (4 worldwide citation)

The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.


9
Thomas Dudler, Wayne R Gombotz, James Brian Parent, Clark E Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov: Compositions for inhibiting MASP-2 dependent complement activation. Omeros Corporation, Tineka J Quinton, Marcia S Kelbon, October 25, 2016: US09475885

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.


10
Thomas Dudler, Wayne R Gombotz, James Brian Parent, Clark E Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov: Compositions for inhibiting MASP-2 dependent complement activation. Omeros Corporation, Tineka J Quinton, Marcia S Kelbon, August 14, 2018: US10047165

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.